DANA-FARBER CANCER INSTITUTE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1947-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.dana-farber.org/
Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Population: The INFORM Study
- Conditions
- Cancer Predisposition SyndromePredisposition, Genetic
- Interventions
- Other: GRAIL Galleri Test
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 1000
- Registration Number
- NCT06450171
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
- Conditions
- Stage IV Breast CancerBreast Cancer MetastaticBreast Cancer FemaleBreast CancerEstrogen Receptor-positive Breast CancerHER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 72
- Registration Number
- NCT06439693
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
ALPINE: Maintenance Letrozole/Abemaciclib Vs Pembrolizumab
- Conditions
- Endometrial CancerRecurrent Endometrial CancerTP53
- Interventions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 76
- Registration Number
- NCT06366347
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
PediCARE Health Equity Intervention in High-Risk Neuroblastoma
- Conditions
- PovertyHigh-risk NeuroblastomaNeuroblastomaDisparitiesFinancial StressPediatric Cancer
- Interventions
- Behavioral: PediCARE Intervention
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT06335745
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
- Conditions
- Breast CancerBreast Cancer Female
- Interventions
- Behavioral: Exercise Training Program
- First Posted Date
- 2024-03-21
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 46
- Registration Number
- NCT06322888
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
- Conditions
- Platinum-resistant Ovarian CancerOvarian CarcinomaOvarian Carcinoma, RecurrentRecurrent Ovary CancerOvarian Cancer
- Interventions
- Biological: Cytokine-Induced Memory-like Natural Killer Cells
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 18
- Registration Number
- NCT06321484
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Memory-like Natural Killer (NK) Cell Therapy With N-803 in Patients With Renal Cell Carcinoma or Urothelial Carcinoma
- Conditions
- Renal CarcinomaRenal Cell CarcinomaUrothelial CarcinomaChromophobe Renal Cell Carcinoma
- Interventions
- Biological: Cytokine Induced Memory-like Natural Killer (CIML NK) Cells
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 5
- Registration Number
- NCT06318871
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer
- Conditions
- Prostate CancerMetastatic Prostate CancerMetastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 37
- Registration Number
- NCT06303713
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
- Conditions
- Advanced MelanomaSkin CancerMelanoma (Skin)
- Interventions
- Behavioral: Exercise ProgramBehavioral: Diet Program
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT06298734
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
PediRISE Feasibility
- Conditions
- Pediatric CancerFinancial StressFinancial HardshipDisparities
- Interventions
- Behavioral: PediRISE Resource Program
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT06283251
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States